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Abstract
Clinical observations suggest that antipsychotic effect starts early and increases progressively over time. This time course of
antipsychotic effect can be captured in a rat phencyclidine (PCP)-induced hyperlocomotion model, as repeated antipsychotic
treatment progressively increases its inhibition of the repeated PCP-induced hyperlocomotion. Although the neural basis
of acute antipsychotic action has been studied extensively, the system that mediates the potentiated effect of repeated antipsychotic treatment has not been elucidated. In the present study, we investigated the neuroanatomical basis of the potentiated action of haloperidol (HAL) and clozapine (CLZ) treatment in the repeated PCP-induced hyperlocomotion. Once daily
for five consecutive days, adult Sprague–Dawley male rats were first injected with HAL (0.05 mg/kg, sc), CLZ (10.0 mg/
kg, sc) or saline, followed by an injection of PCP (3.2 mg/kg, sc) or saline 30 min later, and motor activity was measured for
90 min after the PCP injection. C-Fos immunoreactivity was assessed either after the acute (day 1) or repeated (day 5) drug
tests. Behaviorally, repeated HAL or CLZ treatment progressively increased the inhibition of PCP-induced hyperlocomotion throughout the five days of drug testing. Neuroanatomically, both acute and repeated treatment of HAL significantly increased PCP-induced c-Fos expression in the nucleus accumbens shell (NAs) and the ventral tegmental area (VTA), but reduced it in the central amygdaloid nucleus (CeA). Acute and repeated CLZ treatment significantly increased PCP-induced
c-Fos expression in the ventral part of lateral septal nucleus (LSv) and VTA, but reduced it in the medial prefrontal cortex
(mPFC). More importantly, the effects of HAL and CLZ in these brain areas underwent a time-dependent reduction from
day 1 to day 5. These findings suggest that repeated HAL achieves its potentiated inhibition of the PCP-induced hyperlocomotion by acting on the NAs, CeA and VTA, while CLZ does so by acting on the mPFC, LSv and VTA.
Keywords: Antipsychotic sensitization, Clozapine, c-Fos, Haloperidol, PCP-induced hyperlocomotion
Abbreviations: CeA, central amygdaloid nucleus; CLZ, clozapine; DLSt, dorsolateral striatum; HAL, haloperidol; LS, lateral
septal nucleus; LSv, ventral part of lateral septal nucleus; MeA, medial amygdaloid nucleus; mPFC, medial prefrontal cortex; NA, nucleus accumbens; NAc, nucleus accumbens core; NAs, nucleus accumbens shell; PCP, phencyclidine; VTA, ventral tegmental area

studies of the efficacy of amisulpride in patients with schizophrenia spectrum disorders and found the same results. More
improvement occurs in the first few days than in any later period of equal duration (Leucht et al., 2005). Subsequent studies show that the onset occurs within the first day, contemporaneous with the blockade of dopamine receptors (Kapur et al.,
2005), and early nonimprovement (< 20% reduction in Brief Psychiatric Rating Scale total score at 1 week) predicts nonresponse
at 4 weeks (Correll et al., 2003).
Animal models play an important role in delineating the
time course of antipsychotic action and related behavioral mechanisms (Abekawa et al., 2007; Sun et al., 2009). Among many animal models of antipsychotic drugs, the phencyclidine (PCP)-induced hyperlocomotion model seems especially useful for this
purpose. First, the PCP model is sensitive to antipsychotic action. Antipsychotic drugs, both typical (haloperidol), and atypical (clozapine, olanzapine, risperidone, aripiprazole) acutely

1. Introduction
A growing number of clinical studies suggest that antipsychotic
action starts early and increases in magnitude with repeated
treatment (Agid et al., 2003, 2006; Emsley et al., 2006; Glick et al.,
2006; Kapur et al., 2005; Leucht et al., 2005; Raedler et al., 2007).
This observation is strongly supported by the finding that improvement of psychotic symptoms occurs within the first week
of treatment and shows a progressive increase over the subsequent weeks. For example, Agid et al. (2003) examined 42 double-blind, comparator-controlled studies (> 7000 patients) using
a meta-analysis technique. They found that psychotic symptoms improved within the first week of treatment and showed
a progressive improvement over subsequent weeks, with the
overall pattern of improvement approximating an exponential
curve. Leucht et al. (2005) analyzed a large homogeneous database of original patient data from 7 randomized, double-blind
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inhibit hyperlocomotion induced by PCP in rodents. Atypical
drugs are less likely to cause extrapyramidal motor syndromes
(EPS) and sustained prolactin elevation in comparison to typicals. They also show a preferential inhibition on the PCP-induced hyperlocomotion over the amphetamine-induced hyperlocomotion, whereas typicals do not seem to possess this
preference. Thus, the PCP model is useful in distinguishing different classes of antipsychotics (Gleason and Shannon, 1997;
Maurel-Remy et al., 1995; Millan et al., 1999). Second, repeated
treatment of antipsychotic drugs progressively potentiates the
inhibition of the PCP-induced hyperlocomotion across multiple
drug testing sessions and prolonged this action within sessions
(Sun et al., 2009), a time course of behavioral changes closely
mimicking clinical effects. This property is not shared by antidepressants or anxiolytics (Sun et al., 2009). Therefore, it appears
that the repeated PCP-induced hyperlocomotion model could
serve as a valid model for the investigation of the neurobiological and behavioral mechanisms of action of repeated antipsychotic treatments.
c-Fos, a protein product of immediate-early gene c-fos has
been used as a molecular biomarker for identifying neuronal activation after a variety of behavioral, environmental, and pharmacological stimuli. In the field of antipsychotic drugs, the ability of antipsychotic drugs to induce c-Fos expression in the
forebrain regions has been closely linked to the action sites of
antipsychotic activity and liability for producing extrapyramidal
side effects (Robertson and Fibiger, 1992; Robertson et al., 1994).
Acute administration of typical antipsychotic haloperidol (HAL)
and atypical drug clozapine (CLZ) produces a different induction pattern of c-Fos expression in the forebrain, with acute HAL
increasing Fos-positive neurons in the dorsolateral striatum
(DLSt), nucleus accumbens shell and core (NAs and NAc), and
lateral septal nucleus (LS) and acute CLZ producing such effects
in the NAs, medial prefrontal cortex (mPFC) (Robertson and
Fibiger, 1992; Robertson et al., 1994). Interestingly, psychotomimetic drugs of abuse such as PCP, amphetamine and MK-801
also increase c-Fos expression in these brain areas (De Leonibus et al., 2002; Habara et al., 2001; Rotllant et al., 2010; Sato et
al., 1997; Zuo et al., 2009). Based on these observations, we postulated that by examining how antipsychotic treatment alters cFos expression induced by PCP in the above mentioned brain
regions at different time points of treatment, we may be able to
identify the neuroanatomical bases of acute and potentiated inhibition of HAL or CLZ treatment on PCP-induced hyperlocomotion. In the present study, we used the c-Fos immunohistochemistry technique, together with a pharmacological tool (i.e. PCP)
and behavioral observations (i.e. motor activity), to delineate the
neural circuitries upon which HAL and CLZ act to achieve their
acute and potentiated inhibitory effects on the PCP-induced hyperlocomotion. Because we considered the c-Fos effect in the
context of antipsychotic activity (i.e. PCP-induced hyperlocomotion), our approach ensured that the brain regions identified are
behaviorally and neurochemically relevant to the specific action
of HAL and CLZ.
2. Methods
2.1. Animals
Male Sprague–Dawley rats (220–250 g upon arrival, Charles
River, Portage, MI) were housed in pairs in transparent polycarbonate cages (48.3 cm × 26.7 cm × 20.3 cm) under 12-hr light/
dark cycle (lights on from 6:30 am to 6:30 pm), with food and
water available ad libitum. All animals were maintained in
our colony with a controlled temperature (21 ± 1 °C) and a relative humidity of 55–60%. Animals were allowed at least one
week of habituation to the animal facility before being used
in experiments. All procedures were approved by the Institutional Animal Care and Use Committee at the University of
Nebraska-Lincoln.

2.2. Drugs
The injection solution of haloperidol (HAL, 5.0 mg/ml ampoules,
Sicor Pharmaceuticals, Inc., Irvine, CA) was obtained by mixing drugs with sterile water. Phencyclidine hydrochloride (PCP,
a gift from NIDA Drug Supply Program) and clozapine (CLZ, a
gift from NIMH Drug Supply Program) were dissolved in 0.9%
saline and 1.0% glacial acetic acid in distilled water, respectively.
We chose haloperidol (0.05 mg/kg, sc) and clozapine (10.0 mg/
kg, sc) because they are clinically relevant doses based on the dopamine D2 receptor occupancy data (50–75% occupancy) (Kapur
et al., 2003) and animal behavioral assessment of antipsychotic
activity (Li et al., 2010, 2011). The dose for PCP was 3.2 mg/kg,
which has been shown to induce a robust hyperlocomotion effect
without causing severe stereotypy (Gleason and Shannon, 1997;
Kalinichev et al., 2008; Sun et al., 2009). Haloperidol, clozapine
and phencyclidine were administered subcutaneously.
2.3. Locomotor activity apparatus
Sixteen activity boxes were housed in a quiet room. The boxes
were 48.3 cm × 26.7 cm × 20.3 cm transparent polycarbonate cages, which were similar to the home cages but were each
equipped with a row of 6 photocell beams (7.8 cm between two
adjacent photobeams) placed 3.2 cm above the floor of the cage.
A computer detected the disruption of the photocell beams and
recorded the number of beam breaks. All experiments were run
during the light cycle from 9 am to 4 pm.
2.4. Experimental procedure
Thirty-two rats were randomly assigned to one of four groups
(n = 8/group): vehicle (water) + vehicle (saline, SAL), vehicle (water) + PCP, haloperidol (0.05 mg/kg) + PCP, clozapine
(10.0 mg/kg) + PCP. After two days of habituation to the testing
room and the testing boxes (30 min/day for 2 days), the drug
test days started. On the first drug day, rats were brought to the
testing room, and injected with vehicle (sterile water), haloperidol (0.05 mg/kg), or clozapine (10.0 mg/kg). They were then immediately placed in locomotor activity boxes for 30 min. At the
end of the 30-min testing, rats were taken out and injected with
either 0.9% saline (sc) or PCP (3.2 mg/kg, sc) and placed back
in the boxes for another 90 min. Locomotor activity (number of
photobeam breaks) was measured in 5 min intervals throughout
the entire 120-min testing session. Half of rats from each group
(4/group) were randomly selected and sacrificed immediately
after the end of the 90-min testing for acute c-Fos assay. The remaining rats were repeatedly tested for another 4 days (a total
of 5 tests) and sacrificed at the end of the last drug test day.
2.5. c-Fos immunohistochemistry
Immediately after the locomotor activity test, all rats were anesthetized with sodium pentobarbital (100.0 mg/kg) and then perfused with 4% paraformaldehyde. Brains were post-fixed and
cryoprotected in 30% sucrose, and coronal sections (40 μm) were
cut on a cryostat. Procedures for Fos immunohistochemistry followed the protocol by Zhao and Li (2010). Briefly, sections were
incubated with a rabbit polyclonal anti-c-Fos (Ab-5, PC38) antibody raised against residues 4–17 of human c-Fos (1:20000, Calbiochem, CA, USA) for 48 h at 4 °C. Sections were then incubated with a biotinylated goat anti-rabbit secondary antibody
(1:200, Vector Laboratories, Burlingame, CA, USA) in PBS containing 1% NGS for 2 h at RT. They were processed with avidin–biotin horseradish peroxidase complex (1:200, Vectastain
Elite ABC Kit, Vector Laboratories). The immunoreaction was
visualized with peroxidase substrate (DAB Substrate Kit for
Peroxidase, Vector Laboratories). After staining, sections were
mounted on gelatin-coated slides, air-dried, dehydrated and
coverslipped. As a control, the primary antibody was substi-
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tuted with normal rabbit serum. No corresponding nucleus or
cytoplasm was immunostained in the control.
2.6. Fos-immunoreactive (Fos-I) cell counting
Photomicrographs were captured with a digital camera (INFINITY lite, Canada) equipped with an Olympus CX41RF microscope (Japan) using × 10 objective lens. Fos-I cells characterized
by clearly stained nuclei was counted bilaterally in one section
with comparable anatomical levels across the treatment groups.
The brain regions analyzed included the neural sites that were
either implicated in the action of PCP and/or in the regulation
of locomotor activity [e.g., the medial prefrontal cortex (mPFC),
nucleus accumbens shell (NAs), nucleus accumbens core (NAc),
dorsolateral striatum (DLSt), ventral part of lateral septal nucleus (LSv), medial amygdaloid nucleus (MeA), central amygdaloid nucleus (CeA), and ventral tegmental area (VTA)]. The
levels of brain slices were: Bregma 3.00 mm for mPFC, 1.92 mm
for NAs, NAc and DLSt, 1.44 mm for LSv, − 2.92 mm for MeA
and CeA, − 6.24 mm for VTA according to Paxinos and Watson
(2007) (Figure 1). With the help of ImageJ software (developed
at the US National Institutes of Health), cell counts were made
within a 680 × 510 μm2 unit area of each interest region by an
experimenter blind to the treatment condition. The images were
thresholded and then analyzed. In a given area from distinct
treatments, the images were thresholded to the same value by
means of eliminating background and noise staining to ensure
that the Fos-I cells were selected. The number of Fos-I nuclei of a
given brain region from bilateral sites per rat was averaged. The
values from four rats of each treatment group were averaged to
obtain the final mean ± SEM.
2.7. Statistical analysis
Data for locomotor activity and the number of c-Fos immunoreactive cells were expressed as mean ± SEM and analyzed using
a two-way analysis of variance (ANOVA) with treatment conditions (VEH + VEH, VEH + PCP, HAL + PCP, CLZ + PCP) × test
days (Day1, Day5) as between-subject factors, followed by posthoc Tukey tests to detect two-group difference. Locomotor activity data from each daily test were analyzed using a factorial
repeated measures ANOVA with the between-subjects factor
being the treatment conditions (“Treatment”, e.g. vehicle, HAL
or CLZ in combination with vehicle or PCP), and the withinsubjects factor being the 5-min time block (“Block”, e.g. block for
90 min after PCP injection). A one-way ANOVA was used to test
two-group difference where appropriate. The independent-samples T test was used to compare the acute and repeated effect
of different treatment groups. A conventional two-tailed level
of significance at the 0.05 level was required. Percent inhibition
was calculated by subtracting the motor activity of the HAL/
CLZ + PCP group (T) from the motor activity of the VEH + PCP
group (P), dividing by the motor activity of the VEH + PCP
group, and multiplying by 100[(P – T)/P × 100].
3. Results
3.1. Repeated HAL or CLZ treatment potentiated the inhibition
on the PCP-induced hyperlocomotion
On day 1, PCP significantly increased the mean motor activity
during the 90-min testing period compared to the vehicle treatment [Figure 2, F(3, 12) = 25.14, p < 0.001, post-hoc Tukey tests,
p < 0.001 vs. vehicle]. This psychomotor stimulating effect was
significantly attenuated by pretreatment with HAL (p = 0.008)
and CLZ (p = 0.042). However, in comparison to the vehicle controls, rats treated with HAL + PCP and CLZ + PCP still had significantly higher motor activity (p = 0.004 versus HAL, p < 0.001
versus CLZ), suggesting that the attenuation at the tested doses
was not complete.

Figure 1. Schematic representation of the brain regions (black boxed
areas) sampled for c-Fos immunoreactivity assessment. Distance from
Bregma in the rostrocaudal planes is indicated. Drawings were modified from Paxinos and Watson (2007).

Across the 5 drug test days, repeated PCP treatment tended
to progressively increase locomotor activity. In contrast, repeated HAL and CLZ pretreatment progressively enhanced
their efficacy in inhibiting PCP-induced hyperlocomotion.
A two-way repeated measures ANOVA revealed a main effect of “Treatment” [F(3, 12) = 90.31, p < 0.001], no main effect of
“Day” [F(4, 48) = 1.53, p = 0.21], but a significant interaction between “Treatment” and “Day” [F(12, 48) = 1.89, p = 0.046]. The
enhanced inhibition by repeated HAL and CLZ treatment was
also revealed by the percent inhibition measure. According to
this measure, HAL reduced PCP-induced hyperlocomotion by
45% on day 1, but 77% on day 5. Similarly, CLZ reduced PCPinduced hyperlocomotion by 29% on day 1, but up to 49% on
day 5.
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measures ANOVA revealed a main effect of “Treatment” [F(3,
12) = 25.14, p < 0.001 for day 1; F(3, 12) = 18.55, p < 0.001 for day 5],
a main effect of “Time” [F(17, 204) = 4.63, p < 0.001 for day 1; F(17,
204) = 8.52, p < 0.001 for day 5], and a significant interaction between “Treatment” and “Time” [F(51, 204) = 2.32, p < 0.001 for day
1; F(51, 204) = 5.38, p < 0.001 for day 5]. With repeated treatment,
HAL and CLZ prolonged their inhibition of PCP-induced hyperlocomotion. For example, on day 1, the significant inhibitory
effect of HAL and CLZ started at the 15-min testing point after
the PCP injection, and lasted for the remainder of the test session (Figure 3a, all ps < 0.05 in comparison to the vehicle + PCP
group). On day 5, the significant inhibition advanced to the 10min point (Figure 3b, all ps < 0.05).

Figure 2. Effects of repeated haloperidol or clozapine treatment on
PCP-induced hyperlocomotion over the five test days. Bars represent
means ± SEM. * p < 0.05 versus VEH + VEH control; # p < 0.05 versus VEH + PCP group; &,$ p < 0.05 between Day 1, Day 2 and Day 4,
Day 5.

3.2. Repeated HAL or CLZ treatment prolonged the time course
of the inhibitory action on PCP-induced hyperlocomotion
within session
Figure 3 shows the time course (measured in 5-min blocks for
the 90-min period after PCP administration) of the effects of
HAL or CLZ pretreatment on PCP-induced hyperlocomotion
on the first and last days of drug testing. The two-way repeated

3.3. Effects of acute HAL or CLZ treatment on PCP-induced cFos immunoreactivity
A one-way ANOVA revealed a significant effect in the mPFC
[F(3, 12) = 27.64, p < 0.001], NAs [F(3, 12) = 59.14, p < 0.001], NAc [F(3,
12) = 14.03, p < 0.001], DLSt [F(3, 12) = 104.18, p < 0.001], LSv [F(3,
12) = 24.14, p < 0.001], CeA [F(3, 12) = 77.04, p < 0.001], VTA [F(3,
12) = 250.05, p < 0.001]. In comparison to the vehicle treatment,
acute PCP treatment significantly increased the number of cFos positive cells in the mPFC (p < 0.001), NAs (p < 0.001), NAc
(p = 0.016), LSv (p = 0.021), CeA (p < 0.001) and VTA (p < 0.001),
while having no detectable effect in the DLSt and MeA (Figure 4a). Acute HAL pretreatment further increased c-Fos expression induced by PCP in the NAs, NAc and VTA (all ps < 0.05),

Figure 3. Time course effect of haloperidol or clozapine treatment on PCP-induced hyperlocomotion on test day 1 (a) and day 5 (b). Locomotor activity was measured over 18 5-min blocks and expressed as mean ± SEM for each group. # p < 0.05 versus VEH + PCP group.
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Figure 4. Effects of acute treatment of PCP alone (a), and in combination with haloperidol or clozapine (b) on c-Fos expression in rat brain.
Data were expressed as mean ± SEM. * p < 0.05 versus VEH + VEH
control, # p < 0.05 versus VEH + PCP group.

Figure 5. Effects of repeated treatment of PCP alone (a), and in combination with haloperidol or clozapine (b) on c-Fos expression
in rat brain. Data were expressed as mean ± SEM. * p < 0.05 versus
VEH + VEH control, # p < 0.05 versus VEH + PCP group.

but reduced it in the CeA (p = 0.007) (Figure 4b). HAL itself
also increased c-Fos expression in the DLSt where PCP had little effect. Acute CLZ pretreatment significantly increased cFos expression induced by PCP in the LSv (p = 0.002) and VTA
(p < 0.001), but reduced it in the mPFC (p = 0.002) (Figure 4b).
Table 1 summarizes the distinct effects of acute HAL or CLZ
pretreatment on PCP-induced c-Fos increase. Both HAL and
CLZ shared a common action in the VTA in enhancing the PCPinduced c-Fos expression.

ment on PCP-induced c-Fos increase. The differences between
the acute and repeated treatments of PCP, HAL and CLZ were
apparent. For example, acute treatment of PCP increased Fos expression in the NAc, while repeated treatment had no effect. Repeated CLZ treatment further increased PCP-induced Fos expression in the CeA, while acute CLZ treatment had no effect (
Table 1 and Table 2).

3.4. Effects of repeated HAL or CLZ treatment on PCP-induced
c-Fos immunoreactivity

3.5. Differences in c-Fos expression between acute and repeated
drug treatment

A one-way ANOVA revealed a significant effect in the mPFC
[F(3, 12) = 26.62, p < 0.001], NAs [F(3, 12) = 42.28, p < 0.001], NAc
[F(3, 12) = 35.76, p < 0.001], DLSt [F(3, 12) = 62.71, p < 0.001], LSv [F(3,
12) = 51.64, p < 0.001], CeA [F(3, 12) = 94.28, p < 0.001], VTA [F(3,
12) = 85.29, p < 0.001]. Similar to the acute effect, repeated PCP
treatment significantly increased the number of c-Fos positive
cells in the mPFC (p < 0.001), NAs (p = 0.036), LSv (p < 0.001),
CeA (p < 0.001) and VTA (p = 0.023) (Figure 5a). Repeated HAL
treatment resulted in an increase in PCP-induced c-Fos in the
NAs, NAc and VTA (all ps < 0.001), while reduced it in CeA
(p < 0.001) (Figure 5b). Repeated CLZ further increased PCPinduced c-Fos in the LSv (p = 0.006), CeA (p < 0.001) and VTA
(p = 0.001), while reduced it in the mPFC (p = 0.004) (Figure 5b).
Table 2 summarizes the effects of repeated HAL or CLZ treat-

In comparison to acute effects (day 1), repeated treatment (day
5) resulted in a reduction in c-Fos immunoreactivity in most, but
not all brain areas (Figure 6). The two-way ANOVA revealed a
main effect of “Day” for mPFC [F(1, 24) = 12.35, p = 0.002], NAs
[F(1, 24) = 36.53, p < 0.001], NAc [F(1, 24) = 8.05, p = 0.009], DLSt
[F(1, 24) = 70.54, p < 0.001], LSv [F(1, 24) = 20.11, p < 0.001], CeA [F(1,
24) = 91.41, p < 0.001], and VTA [F(1, 24) = 71.14, p < 0.001]. Specifically, the number of c-Fos positive cells was significantly reduced from day 1 to day 5 in the LSv with VEH + VEH (Figure 6a, p = 0.007); in the mPFC (p = 0.041), NAs (p = 0.006), NAc
(p = 0.004), CeA (p = 0.006) and VTA (p = 0.003) with VEH + PCP
(Figure 6b); in the mPFC (p = 0.015), NAs (p = 0.011), DLSt
(p < 0.001), CeA (p < 0.001) and VTA (p = 0.001) with HAL + PCP
(Figure 6c); and in the mPFC (p = 0.048), NAs (p = 0.003), DLSt
(p = 0.02), LSv (p = 0.003), CeA (p = 0.007) and VTA (p = 0.016)
with CLZ + PCP (Figure 6d).

Table 1. Effects of acute HAL or CLZ pretreatment on PCP-induced
c-Fos expression in rat brain.

Table 2. Effects of repeated HAL or CLZ pretreatment on PCPinduced c-Fos expression in rat brain.

Treatment

mPFC NAs

NAc

DLSt

LSv MeA

CeA

Treatment

mPFC NAs NAc DLSt

LSv MeA

CeA

VTA

VEH + PCP
HAL + PCP
CLZ + PCP

Δ
―
↓

Δ
↑
―

†
↑
―

Δ
―
↑

Δ
↓
―

VEH + PCP
HAL + PCP
CLZ + PCP

Δ
―
↓

Δ
―
↑

Δ
↓
↑

Δ
↑
↑

Δ
↑
―

†
―
―

VTA
Δ
↑
↑

Δ, increase; †, no significant effect relative to VEH + VEH control;
↑, increase; ↓, decrease; ―, no significant effect relative to VEH + PCP
treatment.

Δ
↑
―

†
↑
―

†
↑
―

†
―
―

Δ, increase; †, no significant effect relative to VEH + VEH control;
↑, increase; ↓, decrease; ―, no significant effect relative to VEH + PCP
treatment.
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Figure 6. Effects of acute and repeated treatment of haloperidol or clozapine on PCP-induced c-Fos expression in rat brain. c-Fos expression was
assessed in four distinct groups: VEH + VEH (a), VEH + PCP (b), HAL + PCP (c) and CLZ + PCP (d). Data were expressed as mean ± SEM. *
p < 0.05 between Day 1 and Day 5.

3.6. c-Fos identification of brain regions involved in the potentiation of inhibitory effect of repeated HAL or CLZ treatment on
PCP-induced hyperlocomotion
Based on the changes of c-Fos expression, a brain region had
to meet the following three criteria in order to be considered
as part of the neural circuit(s) by which HAL and CLZ act to
achieve their potentiated inhibitory effect on the PCP-induced
hyperlocomotion. First, it should show altered c-Fos expression
in response to both acute and repeated treatment of PCP. Second, it should show altered PCP-induced c-Fos expression in response to acute and repeated treatment of HAL or CLZ. Third, it
should show a change in c-Fos expression from day 1 to day 5.
Based on these criteria, three regions including NAs, CeA and
VTA could be classified as part of the HAL neural circuit, and
three regions including mPFC, LSv and VTA as part of the CLZ
neural circuit. Table 3 summarizes the results of how these regions met these criteria.
Table 3. Brain regions considered to be part of the neural circuit
through which HAL and CLZ act to achieve their potentiated inhibitory effect on PCP-induced hyperlocomotion using neuronal marker
of c-Fos.
Brain regions

mPFC NAs

LSv

CeA

Criterion 1 (PCP effect)
Δ
Δ
Δ
Δ
Criterion 2 (response to HAL)		
↑		
↓
Criterion 2 (response to CLZ)
↓		
↑		
Criterion 3 (change from acute +
+
+
+
to repeated treatment)

VTA
Δ
↑
↑
+

Δ, increase relative to VEH + VEH control; ↑, increase; ↓, decrease
relative to VEH + PCP treatment; +, change from acute to repeated
treatment.

4. Discussion
The present study differs from most other studies in the literature in which it examined the repeated effects of HAL and CLZ
treatment on the neuronal activities (as indexed by the c-Fos expression) in a validated animal model of antipsychotic activity (i.e. the PCP hyperlocomotion model). Most studies in this
field only focus on the acute effects of antipsychotic treatment
in normal animals (Robertson and Fibiger, 1992; Robertson et al.,
1994). The present study filled these knowledge gaps. Behaviorally, we replicated our previous finding that repeated antipsychotic treatment progressively potentiates the inhibition of the
PCP-induced hyperlocomotion, a behavioral pattern closely resembling the characteristics of time course of antipsychotic actions in the clinic (Sun et al., 2009). Furthermore, we delineated
possible neuronal mechanisms of the time course of antipsychotic action. We showed that both acute and repeated treatment of HAL significantly increased PCP-induced c-Fos expression in the NAs and VTA, while reduced it in the CeA. In
contrast, CLZ treatment enhanced PCP-induced c-Fos in the LSv
and VTA, but reduced it in the mPFC. More importantly, the effects of HAL and CLZ in these brain areas underwent a time-dependent reduction from day 1 to day 5, consistent with their effects at the behavioral levels. These findings indicate that these
brain areas are the likely sites upon which HAL or CLZ act on to
inhibit the psychomotor activation effect of PCP. Thus, we suggest that HAL may achieve its potentiated inhibitory effect on
PCP-induced hyperlocomotion via acting on the NAs, CeA and
VTA, while CLZ does so via the mPFC, LSv and VTA.
Phencyclidine (PCP) has been extensively used to mimic
the positive and negative symptoms of schizophrenia in various animal models (Javitt and Zukin, 1991; Mouri et al., 2007;
Sams-Dodd, 1998). Among many behavioral tasks, the hyperlocomotion model is commonly used as a screening tool for the
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detection of antipsychotic activity. When given acutely, many
antipsychotics inhibit the hyperlocomotor activity induced by
acute administrations of PCP (Gleason and Shannon, 1997; Millan et al., 1999). However, this acute effect is limited in its ability to capture the intrinsic antipsychotic efficacy of a drug and
mimic the time course of antipsychotic treatment in the clinic
(Agid et al., 2003; Leucht et al., 2005). This is because that the inhibition of PCP induced hyperlocomotion is not exclusively the
property of antipsychotics. Drugs that antagonize 5-HT2A receptors but are not antipsychotics such as LY53857, ritanserin, ketanserin, fananserin, and MDL 100,907 also block PCP-induced
hyperlocomotion (Gleason and Shannon, 1997; Millan et al.,
1999). Therefore, the neural basis of PCP effect or antipsychotic
effect identified through c-Fos immunocytochemistry based on
the acute treatment model is questionable. On the other hand,
repeated administration of PCP induces an array of behavioral
and neurochemical changes that mimic those found in schizophrenia better than acute administration of PCP (Jentsch and
Roth, 1999). More importantly, repeated antipsychotic treatment, but not anxiolytic (e.g. chlordiazepoxide) or antidepressant treatment (e.g. fluoxetine and citalopram) progressively
potentiates the inhibition of the PCP-induced hyperlocomotion
across sessions and prolongs this action within sessions (Redmond et al., 1999; Sun et al., 2009). Because clinical antipsychotic
treatment also requires medications be taken for a prolonged
period of time, and the overall antipsychotic effects show an
exponential curve and reach their full therapeutic benefit in
2–3 weeks (Agid et al., 2006), we postulated that the repeated
PCP-induced hyperlocomotion model based on a repeated antipsychotic treatment regimen could serve as a valid model to
investigate the neurochemical and neural mechanisms of action
of antipsychotic drugs. This was the rationale upon which the
current c-Fos study was based on, and we believe that the brain
regions identified through this approach are behaviorally and
neurochemically relevant to the specific action of HAL and CLZ.
Previous work indicates that PCP treatment induces c-Fos
expression in the brain in a region-specific manner. Acute PCP
treatment is shown to increase c-Fos protein and mRNA expression in the mPFC, piriform, cingulate and insular cortices, nucleus accumbens (NA) and lateral septal nucleus (LS) (Gotoh et
al., 2002; Habara et al., 2001; Kargieman et al., 2007; Näkki et al.,
1996; Sato et al., 1997; Sugita et al., 1996). In the present study, we
also found increased c-Fos expression in the mPFC, NA and LS.
In addition, we found a c-Fos increase in the VTA and CeA, suggesting that the VTA and CeA, together with the mPFC, NA and
LS, are parts of a neural network upon which PCP acts to achieve
its behavioral effects. Indeed, PCP microinfused into the mPFC
was shown to cause a hyperlocomotion, and this motor-stimulating effect was attenuated by pharmacological lesions of the
mPFC (Jentsch et al., 1998). Direct infusion of PCP into the NA
also increased locomotor activity (McCullough and Salamone,
1992). Systemic and site-directed injection of PCP to the NA produced an increase in extracellular dopamine levels in the NA
(Carboni et al., 1989; Hernandez et al., 1988; McCullough and
Salamone, 1992; Millan et al., 1999). Depletion of dopamine by
microinjection of 6-hydroxydopamine (6-OHDA) into the NA or
VTA inhibited the PCP-induced hyperlocomotion (French, 1986;
Steinpreis and Salamone, 1993). Finally, systemic administration
of HAL significantly reduced the hyperlocomotion induced by
intra-accumbens injection of PCP (McCullough and Salamone,
1992). All these findings support the hypothesis that PCP affects
multiple brain areas including the mPFC, NA (shell and core),
CeA and VTA to achieve its psychotomimetic effect.
If this hypothesis is correct, we would also expect that pretreatment of HAL or CLZ should alter PCP-induced c-Fos expression in these brain areas. Indeed, we found that both acute
and repeated pretreatment with HAL significantly increased
PCP-induced c-Fos expression in the NAs and VTA, while reduced it in CeA. Similarly, CLZ pretreatment further increased
PCP-induced c-Fos in the LSv and VTA, while reduced it in
the mPFC (Figs. 4b, 5b). Interestingly, the c-Fos expression in
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these areas underwent a time-dependent reduction from day 1
to day 5, consistent with the observed HAL and CLZ potentiated inhibition of PCP-induced hyperlocomotion from day 1 to
day 5. This pattern of change in c-Fos expression over the repeated treatment period has been reported before in the studies
of drugs of abuse (Hope et al., 1992; Persico et al., 1993; Rosen
et al., 1994; Salminen et al., 1999), antipsychotic drugs (Atkins
et al., 1999; Coppens et al., 1995; Hiroi and Graybiel, 1996; Sebens et al., 1995) and chronic stress (Melia et al., 1994; Stamp
and Herbert, 1999; Umemoto et al., 1997). The exact mechanism
responsible for this time-dependent c-Fos reduction is still not
clear. It may be an intrinsic neuroadaptation of the brain in response to various stimuli.
The mechanism of action of PCP is complex (Jentsch and
Roth, 1999). Besides blocking NMDA receptor channels, PCP
can enhance serotonergic, dopaminergic and glutamatergic neurotransmission in the NA and PFC (Abekawa et al., 2007; Maurel-Remy et al., 1995; Millan et al., 1999). Because typical antipsychotics with preferential action on D2 receptors such as
HAL, and atypicals drugs with mixed D2-like/5-HT2A antagonism such as CLZ and olanzapine all inhibit the PCP-induced
hyperlocomotion (Gleason and Shannon, 1997; Maurel-Remy et
al., 1995; Millan et al., 1999), and other 5-HT2A antagonists such
as LY53857, ritanserin, ketanserin, fananserin, and MDL 100,
907, but not 5-HT1A or 5-HT3 antagonists such as WAY 100,635
and zatosetron, also reduce the PCP-induced hyperlocomotion
(Gleason and Shannon, 1997; Millan et al., 1999), it has been suggested that the inhibition of PCP-induced hyperlocomotion is
primarily due to multiple actions of antipsychotics on dopamine
D2 and 5-HT2A receptors (Gleason and Shannon, 1997; MaurelRemy et al., 1995; Millan et al., 1999). This hypothesis is further
supported by the findings that depletion of 5-HT in the NA by
parachloroamphetamine abolishes PCP-induced hyperlocomotion (Millan et al., 1999); M100907, a selective 5-HT2A receptor
antagonist, attenuated PCP-induced c-Fos in the NA, insular
cortex and piriform cortex (Habara et al., 2001); and blockade of
dopamine D2 receptors reduced the extracellular dopamine levels in the NA (McCullough and Salamone, 1992). So for HAL,
we suggest that its potentiated inhibition of the PCP-induced
hyperlocomotion is due to its D2 antagonism in the NAs, CeA
or VTA which leads to a reduction of PCP-induced dopamine
increase. Repeated administration of CLZ causes a down-regulation of 5-HT2A receptors in the PFC (Doat-Meyerhoefer et al.,
2005), microinjection of PCP into the prefrontal cortex elicits hyperlocomotion (Abekawa et al., 2007), we speculate that CLZ
may enhance its inhibition of the PCP-induced hyperlocomotion
by down-regulating 5-HT2A receptors and concomitantly decreasing PCP-induced glutamate, dopamine and 5-HT increases
in the mPFC, LSv and VTA (Abekawa et al., 2007).
In conclusion, using the Fos immunoreactivity as markers of
neuronal activation, we showed that typical antipsychotic HAL
appears to achieve its potentiated inhibitory effect on the PCPinduced hyperlocomotion primarily via acting on the NAs, CeA
and VTA, while CLZ works primarily via the mPFC, LSv and
VTA. It should be pointed out that while c-Fos is an important
step in illuminating the differences in neuronal actions between
haloperidol and clozapine in this task, these data should be regarded as one piece of evidence toward delineating the neural basis of these drug effects. Thus, other indices such as neurotransmitter release, receptor density changes should be used
to validate the current findings in future work.
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